Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.65 |
| ▸ | CA12 | O43570 | 5/20 | 0.65 |
| ▸ | CA9 | Q16790 | 5/20 | 0.65 |
| ▸ | CA1 | P00915 | 5/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.65 |
| ▸ | CA3 | P07451 | 2/20 | 0.65 |
| ▸ | CA4 | P22748 | 2/20 | 0.65 |
| ▸ | CA6 | P23280 | 2/20 | 0.65 |
| ▸ | CA5A | P35218 | 2/20 | 0.65 |
| ▸ | CA7 | P43166 | 2/20 | 0.65 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.65 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.65 |
| ▸ | MMP2 | P08253 | 4/20 | 0.61 |
| ▸ | MMP9 | P14780 | 3/20 | 0.60 |
| ▸ | MMP1 | P03956 | 2/20 | 0.60 |
| ▸ | MMP13 | P45452 | 2/20 | 0.60 |
| ▸ | MMP3 | P08254 | 1/20 | 0.60 |
| ▸ | MMP7 | P09237 | 1/20 | 0.60 |
| ▸ | MMP8 | P22894 | 1/20 | 0.59 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2492568 | 0.95 | MMP2 (0.68) | CA2CA12CA9CA1CA14 | |
| SCHEMBL31219603 | 0.83 | MAPT (0.60) | CA2CA12CA9CA1CA14 | |
| SCHEMBL23788364 | 0.82 | CA2 (0.57) | CA2CA12CA9CA1CA14 | |
| SCHEMBL5193258 | 0.82 | MMP2 (0.68) | CA2CA12CA9CA1CA14 | |
| SCHEMBL17526270 | 0.82 | CA2 (0.66) | CA2CA12CA9CA1CA5A | |
| SCHEMBL22492652 | 0.82 | MMP2 (0.68) | CA2CA12CA9CA1CA14 | |
| SCHEMBL7000224 | 0.81 | CA2 (0.51) | CA2CA12CA9CA1CA14 | |
| SCHEMBL4950672 | 0.80 | ALDH1A1 (0.62) | CA2CA12CA9CA1CA14 | |
| SCHEMBL4950680 | 0.80 | ALDH1A1 (0.62) | CA2CA12CA9CA1CA14 | |
| SCHEMBL6422533 | 0.79 | MMP2 (0.92) | MMP2MMP9MMP1MMP13MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719413-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | Animol Discovery, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260092070-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | ANIMOL DISCOVERY INC (US) | 2026-04-02 | — | — | US | disclosed |
| WO-2024246837-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | ANIMOL DISCOVERY, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-8809369-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2668165-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-04 | — | — | EP | disclosed |
| CN-103328449-A | Novel tetrahydroquinoline derivatives | HOFFMANN LA ROCHE | 2013-09-25 | — | — | CN | disclosed |
| WO-2012101068-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | US | disclosed |
| US-20070179180-A1 | Novel m3 muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-02 | — | — | US | disclosed |
| US-5783699-A | MAY BE CONJUGATED TO ANTIGENS, HAPTENS, ANTIBODIES IN IMMUNOASSAYS | ABBOTT LABORATORIES (US) | 1998-07-21 | — | — | US | disclosed |
| US-5669819-A | IMMUNOASSAY | ABBOTT LABORATORIES (US) | 1997-09-23 | — | — | US | disclosed |
| US-5565570-A | REACTING AMINE WITH SULFONYL HALIDE IN INERT SOLVENT IN PRESENCE OF BASE TO FORM METAL SALT OF SULFONAMIDE, ACYLATING WITH ACTIVATED PHENANTHRIDINE-6-CARBOXYLIC ACID TO FORM CHEMILUMINESCENT SALT | ABBOTT LABORATORIES (US) | 1996-10-15 | — | — | US | disclosed |
| US-5545739-A | E.G., 5-METHYL-6-(N-2-CARBOXYETHYL-N=(2-CARBOXYETHYL)-PHENANTHRIDIN IUMCARBOXAMIDE CHLORIDE; IMMUNOASSAYS; STABILITY; SENSITIVITY | ABBOTT LABORATORIES (US) | 1996-08-13 | — | — | US | disclosed |
| US-5543524-A | FORMING A SULFONAMIDE FROM AND AMINE AND A SULFONYL HALIDE AND AND ACYLATING WITH A CARBONYL HALIDE OF AN ACTIVATED ACRIDINE SALT | ABBOTT LABORATORIES (US) | 1996-08-06 | — | — | US | disclosed |
| US-5468646-A | Chemiluminescent acridinium salts | ABBOTT LABORATORIES (US) | 1995-11-21 | — | — | US | disclosed |
| EP-0273115-B1 | Chemiluminescent acridinium and phenanthridinium salts | ABBOTT LAB (US) | 1994-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179180-A1 | Novel m3 muscarinic acetylcholine receptor antagonists | CHRM3, CHRM2, CHRNA3 | CA2 1234/4885CA12 1787/4885CA9 3667/4885 |
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | RAB1A, RABL3, RAB7A | CA2 3809/4885CA12 4462/4885CA9 4194/4885 |
| US-20260092070-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | JAK1, JAK3, JAK2 | CA2 1072/4885CA12 4095/4885CA9 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.